

# PROCESS FOR OBTAINING HUMAN BROWN/BEIGE ADIPOCYTES

Over one billion adults are either overweight or obese and more than 150 million adults have diabetes.

Adipose tissues play an important role in obesity, insulin resistance and diabetes. White Adipose Tissue (WAT) is the primary site of depot of triglycerides and release of fatty acids. Brown Adipose Tissue (BAT) is specialized in thermogenic energy expenditure through the expression of uncoupling protein-1 (UCP-1).

Recently, a third type of fully differentiated adipocyte defined as brite or beige was shown to be inversely correlated with obesity. This suggests that increasing the relative proportion of brown/beige adipocytes may increase whole body energy expenditure preventing or curing obesity associated diseases.

EFS research laboratory located in Toulouse developed a novel method for producing adipogenic progenitors from human white adipose tissue or mesenchymal stem cells and further differentiating them into functional brown/beige adipocytes which can be used for therapeutic or screening applications

## INVENTION:

A new process for producing brown/beige adipocytes from adult human subcutaneous WAT or mesenchymal stem cells

## KEYWORDS:

Obesity treatment, metabolic disorders, diabetes type 2 treatment, white adipose tissue (WAT), brown adipose tissue (BAT), beige adipocytes, cell-based therapy, mesenchymal stem cells, screening method

## DESCRIPTION:

This process of brown/beige adipocytes production is obtained after 15 days of culture consisting in an expansion step (6-7 days) of adipocyte progenitors and a differentiation step (6-7 days) for obtaining brown/beige adipocytes.

## ADVANTAGES:

- Simple, fast and reproducible process
- Low cost
- Human cells without genetic modification

## APPLICATIONS:

- Cell therapy: administration of brown/beige adipocytes to decrease fat stores or weight
- Screening of compounds: stimulate or inhibit the shifting of white adipocytes into brown/beige adipocytes

## REFERENCE

Muller et al. 2019 Nature Scientific Reports

## CONTACTS

### Research team

STROMALAB  
INSERM 1031  
Louis Casteilla  
louis.casteilla@inserm.fr  
Phone: +33 4 67 61 64 57

### Technology transfer office

Kenza BELHAJ PhD  
Head of IP & TT department  
Kenza.belhaj@efs.sante.fr  
Phone: +33 1 55 93 28 35

Hanaa SAFYA PhD  
Technology Transfer Officer  
hanaa.safya@efs.sante.fr  
Phone: +33 1 55 93 34 30

EFS-Direction  
de la Valorisation  
des Innovations

20 avenue du Stade de  
France  
93218 La Plaine Saint Denis,  
CEDEX, France  
www.efs.sante.fr

## INTELLECTUAL PROPERTY

WO2017009263  
CN 108350423  
HK 1250379  
BR 20181100470  
US 2018/0216070  
EP 3320086  
CA 2991523